Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases

Frontiers in Pharmacology

Volumn 8, Issue MAY, 2017, Pages

  Fenini, Gabriele ^a   Contassot, Emmanuel ^a   French, Lars E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

IL 1; IL 18; IL 1alpha; IL 1beta; Inflammasome; Inflammatory skin conditions

Indexed keywords

3 HYDROXYBUTYRIC ACID; ABSENT IN MELANOMA 2; ANAKINRA; BELNACASAN; CANAKINUMAB; CRYOPYRIN; CURCUMIN; CYTOKINE RECEPTOR ANTAGONIST; GEVOKIZUMAB; GLIBENCLAMIDE; GSK 1070806; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; LY 2189102; MCC 950; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MABP1; NLR PYD CONTAINING PROTEIN 1; NLR PYD CONTAINING PROTEIN 4; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PRALNACASAN; PYRIN; RESVERATROL; RETINOIC ACID INDUCIBLE PROTEIN I; RILONACEPT; TUMOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE VULGARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT ONSET STILL DISEASE; AMICROBIAL PUSTULOSIS OF THE SKIN FOLD; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; BLAU SYNDROME; CINCA SYNDROME; DERMATITIS; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY; MALASSEZIA DERMATITIS; MEVALONATE KINASE DEFICIENCY; MUCKLE WELLS SYNDROME; NONHUMAN; PAPA SYNDROME; PASH SYNDROME; PSORIASIS; PUSTULAR PSORIASIS; PUSTULOSIS; PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SAPHO SYNDROME; SCHNITZLER SYNDROME; SIGNAL TRANSDUCTION; SUPPURATIVE HIDRADENITIS; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 85019622950     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00278     Document Type: Review

References (257)

1. Afonina, I. S., Muller, C., Martin, S. J., and Beyaert, R. (2015). Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 42, 991-1004. doi: 10.1016/j.immuni.2015.06.003
2. Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., et al. (2009). An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426-2437. doi: 10.1056/NEJMoa0807865
3. Aksentijevich, I., Nowak, M., Mallah, M., Chae, J. J., Watford, W. T., Hofmann, S. R., et al. (2002). De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46, 3340-3348. doi: 10.1002/art.10688
4. Alpsoy, E. (2016). Behcet's disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J. Dermatol. 43, 620-632. doi: 10.1111/1346-8138.13381
5. Altiok, E., Aksoy, F., Perk, Y., Taylan, F., Kim, P. W., Ilikkan, B., et al. (2012). A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset. Clin. Immunol. 145, 77-81. doi: 10.1016/j.clim.2012.08.003
6. Amazan, E., Ezzedine, K., Mossalayi, M. D., Taieb, A., Boniface, K., and Seneschal, J. (2014). Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinra. J. Am. Acad. Dermatol. 71, e53-e56. doi: 10.1016/j.jaad.2013.12.041
7. Antin, J. H., Weinstein, H. J., Guinan, E. C., McCarthy, P., Bierer, B. E., Gilliland, D. G., et al. (1994). Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84, 1342-1348
8. Antin, J. H., Weisdorf, D., Neuberg, D., Nicklow, R., Clouthier, S., Lee, S. J., et al. (2002). Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100, 3479-3482. doi: 10.1182/blood-2002-03-0985
9. Aróstegui, J. I., Anton, J., Calvo, I., Robles, A., Speziale, A., Joubert, Y., et al. (2015). Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study. Pediatr. Rheumatol. Online J. 13(Suppl. 1), O58. doi: 10.1186/1546-0096-13-S1-O58
10. Aróstegui, J. I., Arnal, C., Merino, R., Modesto, C., Antonia Carballo, M., Moreno, P., et al. (2007). NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 56, 3805-3813. doi: 10.1002/art.22966
11. Assier, E., Bessis, N., Zagury, J. F., and Boissier, M. C. (2017). IL-1 vaccination is suitable for treating inflammatory diseases. Front. Pharmacol. 8:6. doi: 10.3389/fphar.2017.00006
12. Bachetti, T., and Ceccherini, I. (2014). Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases. J. Mol. Med. 92, 583-594. doi: 10.1007/s00109-014-1150-5
13. Beeson, P. B. (1948). Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytes. J. Clin. Invest. 27:524
14. Ben-Zvi, I., Kukuy, O., Giat, E., Pras, E., Feld, O., Kivity, S., et al. (2017). Anakinra for colchicine resistant familial Mediterranean fever-A randomized, double blind, placebo-controlled trial. Arthritis Rheumatol. 69, 854-862. doi: 10.1002/art.39995
15. Berger, R., Smit, G. P., Schierbeek, H., Bijsterveld, K., and le Coultre, R. (1985). Mevalonic aciduria: an inborn error of cholesterol biosynthesis? Clin. Chim. Acta 152, 219-222. doi: 10.1016/0009-8981(85)90195-0
16. Bihorel, S., Fiedler-Kelly, J., Ludwig, E., Sloan-Lancaster, J., and Raddad, E. (2014). Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. AAPS J. 16, 1009-1017. doi: 10.1208/s12248-014-9623-6
17. Blech, M., Peter, D., Fischer, P., Bauer, M. M., Hafner, M., Zeeb, M., et al. (2013). One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1beta. J. Mol. Biol. 425, 94-111. doi: 10.1016/j.jmb.2012.09.021
18. Bodar, E. J., Kuijk, L. M., Drenth, J. P., van der Meer, J. W., Simon, A., and Frenkel, J. (2011). On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann. Rheum. Dis. 70, 2155-2158. doi: 10.1136/ard.2011.149922
19. Bodar, E. J., van der Hilst, J. C., Drenth, J. P., van der Meer, J. W., and Simon, A. (2005). Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63, 260-264
20. Boraschi, D., and Tagliabue, A. (2013). The interleukin-1 receptor family. Semin. Immunol. 25, 394-407. doi: 10.1016/j.smim.2013.10.023
21. Bossaller, L., Chiang, P. I., Schmidt-Lauber, C., Ganesan, S., Kaiser, W. J., Rathinam, V. A., et al. (2012). Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner. J. Immunol. 189, 5508-5512. doi: 10.4049/jimmunol.1202121
22. Braddock, M., and Quinn, A. (2004). Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 3, 330-339. doi: 10.1038/nrd1342
23. Braun-Falco, M., Kovnerystyy, O., Lohse, P., and Ruzicka, T. (2012). Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J. Am. Acad. Dermatol. 66, 409-415. doi: 10.1016/j.jaad.2010.12.025
24. Brenner, M., Ruzicka, T., Plewig, G., Thomas, P., and Herzer, P. (2009). Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 161, 1199-1201. doi: 10.1111/j.1365-2133.2009.09404.x
25. Brik, R., Butbul-Aviel, Y., Lubin, S., Ben Dayan, E., Rachmilewitz-Minei, T., Tseng, L., et al. (2014). Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 66, 3241-3243. doi: 10.1002/art.38777
26. Brizi, M. G., Galeazzi, M., Lucherini, O. M., Cantarini, L., and Cimaz, R. (2012). Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann. Intern. Med. 156, 907-908. doi: 10.7326/0003-4819-156-12-201206190-00027
27. Bruzzese, V. (2012). Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor alpha therapy. J. Clin. Rheumatol. 18, 413-415. doi: 10.1097/RHU.0b013e318278b84c
28. Brydges, S. D., Broderick, L., McGeough, M. D., Pena, C. A., Mueller, J. L., and Hoffman, H. M. (2013). Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J. Clin. Invest. 123, 4695-4705. doi: 10.1172/JCI71543
29. Brydges, S. D., Mueller, J. L., McGeough, M. D., Pena, C. A., Misaghi, A., Gandhi, C., et al. (2009). Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30, 875-887. doi: 10.1016/j.immuni.2009.05.005
30. Burger, D., Chicheportiche, R., Giri, J. G., and Dayer, J. M. (1995). The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J. Clin. Invest. 96, 38-41. doi: 10.1172/JCI118045
31. Calderon-Castrat, X., Bancalari-Diaz, D., Roman-Curto, C., Romo-Melgar, A., Amoros-Cerdan, D., Alcaraz-Mas, L. A., et al. (2016). PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br. J. Dermatol. 175, 194-198. doi: 10.1111/bjd.14383
32. Calligaris, L., Marchetti, F., Tommasini, A., and Ventura, A. (2008). The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur. J. Pediatr. 167, 695-696. doi: 10.1007/s00431-007-0547-3
33. Canna, S. W., de Jesus, A. A., Gouni, S., Brooks, S. R., Marrero, B., Liu, Y., et al. (2014). An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140-1146. doi: 10.1038/ng.3089
34. Cantarini, L., Vitale, A., Scalini, P., Dinarello, C. A., Rigante, D., Franceschini, R., et al. (2015). Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin. Rheumatol. 34, 1293-1301. doi: 10.1007/s10067-013-2443-8
35. Carrasco, D., Stecher, M., Lefebvre, G. C., Logan, A. C., and Moy, R. (2015). An open label, phase 2 study of MABp1 monotherapy for the treatment of acne vulgaris and psychiatric comorbidity. J. Drugs Dermatol. 14, 560-564
36. Castaneda, S., Blanco, R., and Gonzalez-Gay, M. A. (2016). Adult-onset Still's disease: advances in the treatment. Best Pract. Res. Clin. Rheumatol. 30, 222-238. doi: 10.1016/j.berh.2016.08.003
37. Cavelti-Weder, C., Timper, K., Seelig, E., Keller, C., Osranek, M., Lassing, U., et al. (2016). Development of an interleukin-1beta vaccine in patients with type 2 diabetes. Mol. Ther. 24, 1003-1012. doi: 10.1038/mt.2015.227
38. Chae, J. J., Wood, G., Masters, S. L., Richard, K., Park, G., Smith, B. J., et al. (2006). The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. U.S.A. 103, 9982-9987. doi: 10.1073/pnas.0602081103
39. Chamot, A. M., Benhamou, C. L., Kahn, M. F., Beraneck, L., Kaplan, G., and Prost, A. (1987). Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Rev. Rhum. Mal. Osteoartic. 54, 187-196
40. Chang, Y. P., Ka, S. M., Hsu, W. H., Chen, A., Chao, L. K., Lin, C. C., et al. (2015). Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy. J. Cell. Physiol. 230, 1567-1579. doi: 10.1002/jcp.24903
41. Chavarria-Smith, J., Mitchell, P. S., Ho, A. M., Daugherty, M. D., and Vance, R. E. (2016). Functional and evolutionary analyses identify proteolysis as a general mechanism for NLRP1 inflammasome activation. PLoS Pathog. 12:e1006052. doi: 10.1371/journal.ppat.1006052
42. Chen, C. J., Kono, H., Golenbock, D., Reed, G., Akira, S., and Rock, K. L. (2007). Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13, 851-856. doi: 10.1038/nm1603
43. Chen, K., Shanmugam, N. K., Pazos, M. A., Hurley, B. P., and Cherayil, B. J. (2016). Commensal bacteria-induced inflammasome activation in mouse and human macrophages is dependent on potassium efflux but does not require phagocytosis or bacterial viability. PLoS ONE 11:e0160937. doi: 10.1371/journal.pone.0160937
44. Cimaz, R. (2016). Systemic-onset juvenile idiopathic arthritis. Autoimmun. Rev. 15, 931-934. doi: 10.1016/j.autrev.2016.07.004
45. Coleman, K. M., Gudjonsson, J. E., and Stecher, M. (2015). Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1alpha, for the treatment of psoriasis. JAMA Dermatol. 151, 555-556. doi: 10.1001/jamadermatol.2014.5391
46. Colina, M., Pizzirani, C., Khodeir, M., Falzoni, S., Bruschi, M., Trotta, F., et al. (2010). Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology 49, 1416-1418. doi: 10.1093/rheumatology/keq074
47. Coll, R. C., Robertson, A. A., Chae, J. J., Higgins, S. C., Munoz-Planillo, R., Inserra, M. C., et al. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248-255. doi: 10.1038/nm.3806
48. de Koning, H. D., Bodar, E. J., Simon, A., van der Hilst, J. C., Netea, M. G., and van der Meer, J. W. (2006). Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann. Rheum. Dis. 65, 542-544. doi: 10.1136/ard.2005.045245
49. de Koning, H. D., Schalkwijk, J., van der Meer, J. W., and Simon, A. (2011). Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. J. Allergy Clin. Immunol. 128, 1352-1354. doi: 10.1016/j.jaci.2011.05.023
50. de Koning, H. D., Schalkwijk, J., van der Ven-Jongekrijg, J., Stoffels, M., van der Meer, J. W., and Simon, A. (2013). Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann. Rheum. Dis. 72, 1634-1638. doi: 10.1136/annrheumdis-2012-202192
51. Delluc, A., Limal, N., Puechal, X., Frances, C., Piette, J. C., and Cacoub, P. (2008). Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann. Rheum. Dis. 67, 278-279. doi: 10.1136/ard.2006.068254
52. Di Paolo, N. C., and Shayakhmetov, D. M. (2016). Interleukin 1alpha and the inflammatory process. Nat. Immunol. 17, 906-913. doi: 10.1038/ni.3503
53. Dierselhuis, M. P., Frenkel, J., Wulffraat, N. M., and Boelens, J. J. (2005). Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 44, 406-408. doi: 10.1093/rheumatology/keh479
54. Dignan, F. L., Clark, A., Amrolia, P., Cornish, J., Jackson, G., Mahendra, P., et al. (2012). Diagnosis and management of acute graft-versus-host disease. Br. J. Haematol. 158, 30-45. doi: 10.1111/j.1365-2141.2012.09129.x
55. Dinarello, C. A. (1996). Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147
56. Dinarello, C. A. (2009). Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550. doi: 10.1146/annurev.immunol.021908.132612
57. Dinarello, C. A. (2011). Blocking interleukin-1beta in acute and chronic autoinflammatory diseases. J. Intern. Med. 269, 16-28. doi: 10.1111/j.1365-2796.2010.02313.x
58. Dinarello, C. A., Goldin, N. P., and Wolff, S. M. (1974). Demonstration and characterization of two distinct human leukocytic pyrogens. J. Exp. Med. 139, 1369-1381. doi: 10.1084/jem.139.6.1369
59. Dinarello, C. A., Novick, D., Kim, S., and Kaplanski, G. (2013). Interleukin-18 and IL-18 binding protein. Front. Immunol. 4:289. doi: 10.3389/fimmu.2013.00289
60. Dinarello, C. A., Renfer, L., and Wolff, S. M. (1977). Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc. Natl. Acad. Sci. U.S.A. 74, 4624-4627. doi: 10.1073/pnas.74.10.4624
61. Dombrowski, Y., Peric, M., Koglin, S., Kammerbauer, C., Goss, C., Anz, D., et al. (2011). Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci. Transl. Med. 3:82ra38. doi: 10.1126/scitranslmed.3002001
62. Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., and Tschopp, J. (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677. doi: 10.1126/science.1156995
63. Drewe, E., Powell, R. J., and McDermott, E. M. (2007). Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 46, 1865-1866. doi: 10.1093/rheumatology/kem231
64. Duchatelet, S., Miskinyte, S., Join-Lambert, O., Ungeheuer, M. N., Frances, C., Nassif, A., et al. (2015). First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome. Br. J. Dermatol. 173, 610-612. doi: 10.1111/bjd.13668
65. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., et al. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361. doi: 10.1038/nature08938
66. Dybowski, F., Sepp, N., Bergerhausen, H. J., and Braun, J. (2008). Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin. Exp. Rheumatol. 26, 354-357
67. Emmi, G., Talarico, R., Lopalco, G., Cimaz, R., Cantini, F., Viapiana, O., et al. (2016). Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study. Clin. Rheumatol. 35, 1281-1286. doi: 10.1007/s10067-015-3004-0
68. Fabiani, C., Vitale, A., Emmi, G., Lopalco, G., Vannozzi, L., Guerriero, S., et al. (2016). Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study. Clin. Rheumatol. 36, 191-197. doi: 10.1007/s10067-016-3506-4
69. FDA (2016). FDA Approves Expanded Indications for Ilaris for Three Rare Diseases. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522283.htm
70. Feldmeyer, L., Keller, M., Niklaus, G., Hohl, D., Werner, S., and Beer, H. D. (2007). The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr. Biol. 17, 1140-1145. doi: 10.1016/j.cub.2007.05.074
71. Feldmeyer, L., Werner, S., French, L. E., and Beer, H. D. (2010). Interleukin-1, inflammasomes and the skin. Eur. J. Cell Biol. 89, 638-644. doi: 10.1016/j.ejcb.2010.04.008
72. Fettelschoss, A., Kistowska, M., LeibundGut-Landmann, S., Beer, H. D., Johansen, P., Senti, G., et al. (2011). Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc. Natl. Acad. Sci. U.S.A. 108, 18055-18060. doi: 10.1073/pnas.1109176108
73. Firinu, D., Garcia-Larsen, V., Manconi, P. E., and Del Giacco, S. R. (2016). SAPHO syndrome: current developments and approaches to clinical treatment. Curr. Rheumatol. Rep. 18, 35. doi: 10.1007/s11926-016-0583-y
74. Franchi, L., Warner, N., Viani, K., and Nunez, G. (2009). Function of Nod-like receptors in microbial recognition and host defense. Immunol. Rev. 227, 106-128. doi: 10.1111/j.1600-065X.2008.00734.x
75. French FMF Consortium (1997). A candidate gene for familial Mediterranean fever. Nat. Genet. 17, 25-31. doi: 10.1038/ng0997-25
76. Gaitanis, G., Magiatis, P., Hantschke, M., Bassukas, I. D., and Velegraki, A. (2012). The Malassezia genus in skin and systemic diseases. Clin. Microbiol. Rev. 25, 106-141. doi: 10.1128/CMR.00021-11
77. Galimberti, R. L., Vacas, A. S., Bollea Garlatti, M. L., and Torre, A. C. (2016). The role of interleukin-1beta in pyoderma gangrenosum. JAAD Case Rep. 2, 366-368. doi: 10.1016/j.jdcr.2016.07.007
78. Gattorno, M., Obici, L., Cattalini, M., Tormey, V., Abrams, K., Davis, N., et al. (2017). Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann. Rheum. Dis. 76, 173-178. doi: 10.1136/annrheumdis-2015-209031
79. Gattorno, M., Pelagatti, M. A., Meini, A., Obici, L., Barcellona, R., Federici, S., et al. (2008). Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 1516-1520. doi: 10.1002/art.23475
80. Gery, I., Gershon, R. K., and Waksman, B. H. (1972). Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J. Exp. Med. 136, 128-142. doi: 10.1084/jem.136.1.128
81. Geusau, A., Mothes-Luksch, N., Nahavandi, H., Pickl, W. F., Wise, C. A., Pourpak, Z., et al. (2013). Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 149, 209-215. doi: 10.1001/2013.jamadermatol.717
82. Giancane, G., Minoia, F., Davi, S., Bracciolini, G., Consolaro, A., and Ravelli, A. (2016). IL-1 inhibition in systemic juvenile idiopathic arthritis. Front. Pharmacol. 7:467. doi: 10.3389/fphar.2016.00467
83. Goh, A. X., Bertin-Maghit, S., Ping Yeo, S., Ho, A. W., Derks, H., Mortellaro, A., et al. (2014). A novel human anti-interleukin-1beta neutralizing monoclonal antibody showing in vivo efficacy. MAbs 6, 765-773. doi: 10.4161/mabs.28614
84. Goldbach-Mansky, R. (2011). Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr. Rheumatol. Rep. 13, 123-131. doi: 10.1007/s11926-011-0165-y
85. Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., et al. (2006). Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355, 581-592. doi: 10.1056/NEJMoa055137
86. Goldbach-Mansky, R., Shroff, S. D., Wilson, M., Snyder, C., Plehn, S., Barham, B., et al. (2008). A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 58, 2432-2442. doi: 10.1002/art.23620
87. Greco, E., Aita, A., Galozzi, P., Gava, A., Sfriso, P., Negm, O. H., et al. (2015). The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-kappaB pathway. Arthritis Res. Ther. 17, 93. doi: 10.1186/s13075-015-0604-7
88. Gringhuis, S. I., Kaptein, T. M., Wevers, B. A., Theelen, B., van der Vlist, M., Boekhout, T., et al. (2012). Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat. Immunol. 13, 246-254. doi: 10.1038/ni.2222
89. Gross, C. J., Mishra, R., Schneider, K. S., Medard, G., Wettmarshausen, J., Dittlein, D. C., et al. (2016). K+ efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria. Immunity 45, 761-773. doi: 10.1016/j.immuni.2016.08.010
90. Gross, O., Yazdi, A. S., Thomas, C. J., Masin, M., Heinz, L. X., Guarda, G., et al. (2012). Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36, 388-400. doi: 10.1016/j.immuni.2012.01.018
91. Gül, A., Ozdogan, H., Erer, B., Ugurlu, S., Kasapcopur, O., Davis, N., et al. (2015). Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res. Ther. 17:243. doi: 10.1186/s13075-015-0765-4
92. Haas, D., and Hoffmann, G. F. (2006). Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J. Rare Dis. 1:13. doi: 10.1186/1750-1172-1-13
93. Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., et al. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9, 857-865. doi: 10.1038/ni.1636
94. Hara, H., Tsuchiya, K., Kawamura, I., Fang, R., Hernandez-Cuellar, E., Shen, Y., et al. (2013). Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat. Immunol. 14, 1247-1255. doi: 10.1038/ni.2749
95. Hashkes, P. J., Spalding, S. J., Giannini, E. H., Huang, B., Johnson, A., Park, G., et al. (2012). Rilonacept for colchicine-resistant or-intolerant familial Mediterranean fever: a randomized trial. Ann. Intern. Med. 157, 533-541. doi: 10.7326/0003-4819-157-8-201210160-00003
96. Hawkins, P. N., Lachmann, H. J., and McDermott, M. F. (2003). Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583-2584. doi: 10.1056/NEJM200306193482523
97. He, W. T., Wan, H., Hu, L., Chen, P., Wang, X., Huang, Z., et al. (2015). Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res. 25, 1285-1298. doi: 10.1038/cr.2015.139
98. He, Y., Zeng, M. Y., Yang, D., Motro, B., and Nunez, G. (2016). NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354-357. doi: 10.1038/nature16959
99. Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Kocsis, J., et al. (2017). MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol doi: 10.1016/S1470-2045(17)30006-2 [Epub ahead of print]
100. Hise, A. G., Tomalka, J., Ganesan, S., Patel, K., Hall, B. A., Brown, G. D., et al. (2009). An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 5, 487-497. doi: 10.1016/j.chom.2009.05.002
101. Hoffman, H. M., Kuemmerle-Deschner, J. B., Hawkins, P. N., Van der Poll, T., Walker, U. A., Speziale, A., et al. (2016). "Safety and efficacy of long-term canakinumab therapy in patients with CAPS: final results from beta-confident registry, " in Proceedings of the 2016 ACR/ARHP Annual Meeting, (Washington, DC: Wiley)
102. Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., and Kolodner, R. D. (2001). Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29, 301-305. doi: 10.1038/ng756
103. Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., et al. (2004). Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785. doi: 10.1016/S0140-6736(04)17401-1
104. Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., et al. (2008). Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452. doi: 10.1002/art.23687
105. Hong, D. S., Hui, D., Bruera, E., Janku, F., Naing, A., Falchook, G. S., et al. (2014). MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 15, 656-666. doi: 10.1016/S1470-2045(14)70155-X
106. Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., et al. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856. doi: 10.1038/ni.1631
107. Hsu, L. C., Ali, S. R., McGillivray, S., Tseng, P. H., Mariathasan, S., Humke, E. W., et al. (2008). A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc. Natl. Acad. Sci. U.S.A. 105, 7803-7808. doi: 10.1073/pnas.0802726105
108. Hua, K. F., Chou, J. C., Ka, S. M., Tasi, Y. L., Chen, A., Wu, S. H., et al. (2015). Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1beta production. J. Cell. Physiol. 230, 863-874. doi: 10.1002/jcp.24815
109. Huang, W., Nath, R., Zayed, H., Rubin, P., Moore, A., Snyder, R., et al. (2014). Results of An Open-Label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum. Available at: http://www.xoma.com/content/pipeline/documents/X052170_AAD2014_Poster_FINAL.pdf [Accessed December 2016]
110. Hull, K. M., Drewe, E., Aksentijevich, I., Singh, H. K., Wong, K., McDermott, E. M., et al. (2002). The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 81, 349-368. doi: 10.1097/00005792-200209000-00002
111. Imhof, L., Meier, B., Frei, P., Kamarachev, J., Rogler, G., Kolios, A., et al. (2015). Severe sweet's syndrome with elevated cutaneous interleukin-1beta after azathioprine exposure: case report and review of the literature. Dermatology 230, 293-298. doi: 10.1159/000371879
112. Infevers. (2017). Infevers: An Online Database for Autoinflammatory Mutations. Available at: http://fmf.igh.cnrs.fr/ISSAID/infevers/ [Accessed March 20, 2017]
113. Ito, M., Shichita, T., Okada, M., Komine, R., Noguchi, Y., Yoshimura, A., et al. (2015). Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat. Commun. 6:7360. doi: 10.1038/ncomms8360
114. Ito, S., Hara, Y., and Kubota, T. (2014). CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction. Arthritis Res. Ther. 16, R52. doi: 10.1186/ar4483
115. Jacobsohn, D. A., and Vogelsang, G. B. (2007). Acute graft versus host disease. Orphanet J. Rare Dis. 2:35. doi: 10.1186/1750-1172-2-35
116. Jaeger, T., Andres, C., Grosber, M., Zirbs, M., Hein, R., Ring, J., et al. (2013). Pyoderma gangrenosum and concomitant hidradenitis suppurativa-rapid response to canakinumab (anti-IL-1beta). Eur. J. Dermatol. 23, 408-410. doi: 10.1684/ejd.2013.2018
117. Jankovic, D., Ganesan, J., Bscheider, M., Stickel, N., Weber, F. C., Guarda, G., et al. (2013). The Nlrp3 inflammasome regulates acute graft-versus-host disease. J. Exp. Med. 210, 1899-1910. doi: 10.1084/jem.20130084
118. Jeru, I., Cochet, E., Duquesnoy, P., Hentgen, V., Copin, B., Mitjavila-Garcia, M. T., et al. (2014). Brief report: involvement of TNFRSF11A molecular defects in autoinflammatory disorders. Arthritis Rheumatol. 66, 2621-2627. doi: 10.1002/art.38727
119. Jeru, I., Duquesnoy, P., Fernandes-Alnemri, T., Cochet, E., Yu, J. W., Lackmy-Port-Lis, M., et al. (2008). Mutations in NALP12 cause hereditary periodic fever syndromes. Proc. Natl. Acad. Sci. U.S.A. 105, 1614-1619. doi: 10.1073/pnas.0708616105
120. Jeru, I., Papin, S., L'Hoste, S., Duquesnoy, P., Cazeneuve, C., Camonis, J., et al. (2005). Interaction of pyrin with 14.3.3 in an isoform-specific and phosphorylation-dependent manner regulates its translocation to the nucleus. Arthritis Rheum. 52, 1848-1857. doi: 10.1002/art.21050
121. Jesus, A. A., and Goldbach-Mansky, R. (2014). IL-1 blockade in autoinflammatory syndromes. Annu. Rev. Med. 65, 223-244. doi: 10.1146/annurev-med-061512-150641
122. Jin, Y., Mailloux, C. M., Gowan, K., Riccardi, S. L., LaBerge, G., Bennett, D. C., et al. (2007). NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 356, 1216-1225. doi: 10.1056/NEJMoa061592
123. Kailasan Vanaja, S., Rathinam, V. A., Atianand, M. K., Kalantari, P., Skehan, B., Fitzgerald, K. A., et al. (2014). Bacterial RNA:DNA hybrids are activators of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. U.S.A. 111, 7765-7770. doi: 10.1073/pnas.1400075111
124. Kanameishi, S., Nakamizo, S., Endo, Y., Fujisawa, A., Dainichi, T., Tanaka, T., et al. (2016). High level of serum human interleukin-18 in a patient with pyogenic arthritis, pyoderma gangrenosum and acne syndrome. J. Eur. Acad. Dermatol. Venereol. 31, e115-e116. doi: 10.1111/jdv.13856
125. Kayagaki, N., Stowe, I. B., Lee, B. L., O'Rourke, K., Anderson, K., Warming, S., et al. (2015). Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666-671. doi: 10.1038/nature15541
126. Kayagaki, N., Warming, S., Lamkanfi, M., Vande Walle, L., Louie, S., Dong, J., et al. (2011). Non-canonical inflammasome activation targets caspase-11. Nature 479, 117-121. doi: 10.1038/nature10558
127. Keller, M., Ruegg, A., Werner, S., and Beer, H. D. (2008). Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831. doi: 10.1016/j.cell.2007.12.040
128. Kim, B., Lee, Y., Kim, E., Kwak, A., Ryoo, S., Bae, S. H., et al. (2013). The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front. Immunol. 4:391. doi: 10.3389/fimmu.2013.00391
129. Kistowska, M., Fenini, G., Jankovic, D., Feldmeyer, L., Kerl, K., Bosshard, P., et al. (2014a). Malassezia yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signalling. Exp. Dermatol. 23, 884-889. doi: 10.1111/exd.12552
130. Kistowska, M., Gehrke, S., Jankovic, D., Kerl, K., Fettelschoss, A., Feldmeyer, L., et al. (2014b). IL-1beta drives inflammatory responses to propionibacterium acnes in vitro and in vivo. J. Invest. Dermatol. 134, 677-685. doi: 10.1038/jid.2013.438
131. Kitamura, A., Sasaki, Y., Abe, T., Kano, H., and Yasutomo, K. (2014). An inherited mutation in NLRC4 causes autoinflammation in human and mice. J. Exp. Med. 211, 2385-2396. doi: 10.1084/jem.20141091
132. Kluger, N., Gil-Bistes, D., Guillot, B., and Bessis, D. (2011). Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet's syndrome. Dermatology 222, 123-127. doi: 10.1159/000326112
133. Kolios, A. G., Maul, J. T., Meier, B., Kerl, K., Traidl-Hoffmann, C., Hertl, M., et al. (2015). Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br. J. Dermatol. 173, 1216-1223. doi: 10.1111/bjd.14037
134. Kong, F., Ye, B., Cao, J., Cai, X., Lin, L., Huang, S., et al. (2016). Curcumin represses NLRP3 inflammasome activation via TLR4/MyD88/NF-kappaB and P2X7R signaling in PMA-induced macrophages. Front. Pharmacol. 7:369. doi: 10.3389/fphar.2016.00369
135. Kontzias, A., and Efthimiou, P. (2012). The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin. Arthritis Rheum. 42, 201-205. doi: 10.1016/j.semarthrit.2012.03.004
136. Krause, K., Tsianakas, A., Wagner, N., Fischer, J., Weller, K., Metz, M., et al. (2017). Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. J. Allergy Clin. Immunol. 139, 1311-1320. doi: 10.1016/j.jaci.2016.07.041
137. Krause, K., Weller, K., Stefaniak, R., Wittkowski, H., Altrichter, S., Siebenhaar, F., et al. (2012). Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 67, 943-950. doi: 10.1111/j.1398-9995.2012.02843.x
138. Kuemmerle-Deschner, J. B., Hachulla, E., Cartwright, R., Hawkins, P. N., Tran, T. A., Bader-Meunier, B., et al. (2011a). Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70, 2095-2102. doi: 10.1136/ard.2011.152728
139. Kuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., et al. (2011b). Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res. Ther. 13, R34. doi: 10.1186/ar3266
140. Kurzen, H., Kurokawa, I., Jemec, G. B., Emtestam, L., Sellheyer, K., Giamarellos-Bourboulis, E. J., et al. (2008). What causes hidradenitis suppurativa? Exp. Dermatol. 17, 455-456; discussion 457-472. doi: 10.1111/j.1600-0625.2008.00712_1.x
141. Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., et al. (2009). Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425. doi: 10.1056/NEJMoa0810787
142. Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., et al. (2009). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187, 61-70. doi: 10.1083/jcb.200903124
143. Laskari, K., Boura, P., Dalekos, G. N., Garyfallos, A., Karokis, D., Pikazis, D., et al. (2017). Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever. J. Rheumatol. 44, 102-109. doi: 10.3899/jrheum.160518
144. 2+ and cAMP. Nature 492, 123-127. doi: 10.1038/nature11588
145. Lee, J. K., Kim, S. H., Lewis, E. C., Azam, T., Reznikov, L. L., and Dinarello, C. A. (2004). Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl. Acad. Sci. U.S.A. 101, 8815-8820. doi: 10.1073/pnas.0402800101
146. Leifer, C. A., and Medvedev, A. E. (2016). Molecular mechanisms of regulation of Toll-like receptor signaling. J. Leukoc. Biol. 100, 927-941. doi: 10.1189/jlb.2MR0316-117RR
147. Leslie, K. S., Tripathi, S. V., Nguyen, T. V., Pauli, M., and Rosenblum, M. D. (2014). An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J. Am. Acad. Dermatol. 70, 243-251. doi: 10.1016/j.jaad.2013.09.044
148. Leuenberger, M., Berner, J., Di Lucca, J., Fischer, L., Kaparos, N., Conrad, C., et al. (2016). PASS syndrome: an IL-1-driven autoinflammatory disease. Dermatology 232, 254-258. doi: 10.1159/000443648
149. Li, X., Zhang, C., Chen, W., Pan, B., Kong, F., Zheng, K., et al. (2015). Protective effect of neutralizing anti-IL-18alpha monoclonal antibody on a mouse model of acute graft-versus-host disease. Oncol. Rep. 34, 2031-2039. doi: 10.3892/or.2015.4176
150. Li, Z. J., Choi, D. K., Sohn, K. C., Seo, M. S., Lee, H. E., Lee, Y., et al. (2014). Propionibacterium acnes activates the NLRP3 inflammasome in human sebocytes. J. Invest. Dermatol. 134, 2747-2756. doi: 10.1038/jid.2014.221
151. Lima, A. L., Karl, I., Giner, T., Poppe, H., Schmidt, M., Presser, D., et al. (2016). Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br. J. Dermatol. 174, 514-521. doi: 10.1111/bjd.14214
152. Lindor, N. M., Arsenault, T. M., Solomon, H., Seidman, C. E., and McEvoy, M. T. (1997). A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 72, 611-615. doi: 10.1016/S0025-6196(11)63565-9
153. Lipsker, D., Grattan, C. E. H., and Lovell, C. R. (2016). "Autoinflammatory diseases presenting in the skin, " in Rook's Textbook of Dermatology, eds C. E. M. Griffiths, J. Barker, T. Bleiker, R. Chalmers, and D. Creamer (Hoboken, NJ: John Wiley & Sons, Ltd)
154. Lo Gullo, A., Caruso, A., Pipitone, N., Macchioni, P., Pazzola, G., and Salvarani, C. (2014). Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations. Joint Bone Spine 81, 376-377. doi: 10.1016/j.jbspin.2013.12.011
155. Lovell, D. J., Bowyer, S. L., and Solinger, A. M. (2005). Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283-1286. doi: 10.1002/art.20953
156. Lovell, D. J., Giannini, E. H., Reiff, A. O., Kimura, Y., Li, S., Hashkes, P. J., et al. (2013). Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 65, 2486-2496. doi: 10.1002/art.38042
157. Lupfer, C., and Kanneganti, T. D. (2013). Unsolved mysteries in NLR biology. Front. Immunol. 4:285. doi: 10.3389/fimmu.2013.00285
158. Maekawa, S., Ohto, U., Shibata, T., Miyake, K., and Shimizu, T. (2016). Crystal structure of NOD2 and its implications in human disease. Nat. Commun. 7:11813. doi: 10.1038/ncomms11813
159. Man, S. M., and Kanneganti, T. D. (2016). Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat. Rev. Immunol. 16, 7-21. doi: 10.1038/nri.2015.7
160. Mandey, S. H., Kuijk, L. M., Frenkel, J., and Waterham, H. R. (2006). A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum. 54, 3690-3695. doi: 10.1002/art.22194
161. Mansouri, B., and Menter, A. (2015). Reporting of MABp1 for the treatment of psoriasis. JAMA Dermatol. 151, 1143-1144. doi: 10.1001/jamadermatol.2015.1684
162. Mansouri, B., Richards, L., and Menter, A. (2015). Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br. J. Dermatol. 173, 239-241. doi: 10.1111/bjd.13614
163. Mariathasan, S., Newton, K., Monack, D. M., Vucic, D., French, D. M., Lee, W. P., et al. (2004). Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213-218. doi: 10.1038/nature02664
164. Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., et al. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232. doi: 10.1038/nature04515
165. Martinon, F., Burns, K., and Tschopp, J. (2002). The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell. 10, 417-426. doi: 10.1016/S1097-2765(02)00599-3
166. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241. doi: 10.1038/nature04516
167. Marzano, A. V., Capsoni, F., Berti, E., Gasparini, G., Bottelli, S., and Caputo, R. (1996). Amicrobial pustular dermatosis of cutaneous folds associated with autoimmune disorders: a new entity? Dermatology 193, 88-93
168. Marzano, A. V., Ceccherini, I., Gattorno, M., Fanoni, D., Caroli, F., Rusmini, M., et al. (2014a). Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine 93:e187. doi: 10.1097/MD.0000000000000187
169. Marzano, A. V., Fanoni, D., Antiga, E., Quaglino, P., Caproni, M., Crosti, C., et al. (2014b). Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin. Exp. Immunol. 178, 48-56. doi: 10.1111/cei.12394
170. Marzano, A. V., Trevisan, V., Gattorno, M., Ceccherini, I., De Simone, C., and Crosti, C. (2013). Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 149, 762-764. doi: 10.1001/jamadermatol.2013.2907
171. Masters, S. L. (2013). Specific inflammasomes in complex diseases. Clin. Immunol. 147, 223-228. doi: 10.1016/j.clim.2012.12.006
172. Masters, S. L., Lagou, V., Jeru, I., Baker, P. J., Van Eyck, L., Parry, D. A., et al. (2016). Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci. Transl. Med. 8:332ra345. doi: 10.1126/scitranslmed.aaf1471
173. Mazzoccoli, G., Matarangolo, A., Rubino, R., Inglese, M., and De Cata, A. (2016). Behcet syndrome: from pathogenesis to novel therapies. Clin. Exp. Med. 16, 1-12. doi: 10.1007/s10238-014-0328-z
174. McDermott, M. F., Aksentijevich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., et al. (1999). Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97, 133-144. doi: 10.1016/S0092-8674(00)80721-7
175. McKie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., et al. (2016). A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS ONE 11:e0150018. doi: 10.1371/journal.pone.0150018
176. Meixenberger, K., Pache, F., Eitel, J., Schmeck, B., Hippenstiel, S., Slevogt, H., et al. (2010). Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3. J. Immunol. 184, 922-930. doi: 10.4049/jimmunol.0901346
177. Menis, D., Maronas-Jimenez, L., Delgado-Marquez, A. M., Postigo-Llorente, C., and Vanaclocha-Sebastian, F. (2015). Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br. J. Dermatol. 172, 810-811. doi: 10.1111/bjd.13292
178. Miao, E. A., Mao, D. P., Yudkovsky, N., Bonneau, R., Lorang, C. G., Warren, S. E., et al. (2010). Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc. Natl. Acad. Sci. U.S.A. 107, 3076-3080. doi: 10.1073/pnas.0913087107
179. Miceli-Richard, C., Lesage, S., Rybojad, M., Prieur, A. M., Manouvrier-Hanu, S., Hafner, R., et al. (2001). CARD15 mutations in Blau syndrome. Nat. Genet. 29, 19-20. doi: 10.1038/ng720
180. Munoz-Planillo, R., Franchi, L., Miller, L. S., and Nunez, G. (2009). A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J. Immunol. 183, 3942-3948. doi: 10.4049/jimmunol.0900729
181. Munoz-Planillo, R., Kuffa, P., Martinez-Colon, G., Smith, B. L., Rajendiran, T. M., and Nunez, G. (2013). K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142-1153. doi: 10.1016/j.immuni.2013.05.016
182. Murakami, T., Ockinger, J., Yu, J., Byles, V., McColl, A., Hofer, A. M., et al. (2012). Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. U.S.A. 109, 11282-11287. doi: 10.1073/pnas.1117765109
183. Muruve, D. A., Petrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., et al. (2008). The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103-107. doi: 10.1038/nature06664
184. Nakamura, K., Okamura, H., Nagata, K., Komatsu, T., and Tamura, T. (1993). Purification of a factor which provides a costimulatory signal for gamma interferon production. Infect. Immun. 61, 64-70
185. Nakamura, K., Okamura, H., Wada, M., Nagata, K., and Tamura, T. (1989). Endotoxin-induced serum factor that stimulates gamma interferon production. Infect. Immun. 57, 590-595
186. Navarini, A. A., Satoh, T. K., and French, L. E. (2016). Neutrophilic dermatoses and autoinflammatory diseases with skin involvement-innate immune disorders. Semin. Immunopathol. 38, 45-56. doi: 10.1007/s00281-015-0549-6
187. Neal, D. C. C., Almeida de Jesus, A., Huang, Y., Liu, Y., Goldbach-Mansky, R., and Montealegre, G. (2014). "Safety and efficacy of rilonacept in patients with deficiency of interleukin-1 receptor antagonist (DIRA), " in Proceedings of the 2014 ACR/ARHP Annual Meeting, (Boston, MA: Wiley)
188. Niyonsaba, F., Ushio, H., Nagaoka, I., Okumura, K., and Ogawa, H. (2005). The human beta-defensins (-1,-2,-3,-4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J. Immunol. 175, 1776-1784. doi: 10.4049/jimmunol.175.3.1776
189. Nordstrom, D., Knight, A., Luukkainen, R., van Vollenhoven, R., Rantalaiho, V., Kajalainen, A., et al. (2012). Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J. Rheumatol. 39, 2008-2011. doi: 10.3899/jrheum.111549
190. Okada, M., Matsuzawa, A., Yoshimura, A., and Ichijo, H. (2014). The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J. Biol. Chem. 289, 32926-32936. doi: 10.1074/jbc.M114.579961
191. Park, Y. H., Wood, G., Kastner, D. L., and Chae, J. J. (2016). Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat. Immunol. 17, 914-921. doi: 10.1038/ni.3457
192. Perera, G. K., Di Meglio, P., and Nestle, F. O. (2012). Psoriasis. Annu. Rev. Pathol. 7, 385-422. doi: 10.1146/annurev-pathol-011811-132448
193. Petrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., and Tschopp, J. (2007). Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589. doi: 10.1038/sj.cdd.4402195
194. Petryna, O., Cush, J. J., and Efthimiou, P. (2012). IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann. Rheum. Dis. 71, 2056-2057. doi: 10.1136/annrheumdis-2012-201409
195. Pink, A. E., Simpson, M. A., Desai, N., Dafou, D., Hills, A., Mortimer, P., et al. (2012). Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J. Invest. Dermatol. 132, 2459-2461. doi: 10.1038/jid.2012.162
196. Primiano, M. J., Lefker, B. A., Bowman, M. R., Bree, A. G., Hubeau, C., Bonin, P. D., et al. (2016). Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456, 773 (CRID3) in murine models of dermal and pulmonary inflammation. J. Immunol. 197, 2421-2433. doi: 10.4049/jimmunol.1600035
197. Qin, M., Pirouz, A., Kim, M. H., Krutzik, S. R., Garban, H. J., and Kim, J. (2014). Propionibacterium acnes induces IL-1beta secretion via the NLRP3 inflammasome in human monocytes. J. Invest. Dermatol. 134, 381-388. doi: 10.1038/jid.2013.309
198. Qu, Y., Misaghi, S., Izrael-Tomasevic, A., Newton, K., Gilmour, L. L., Lamkanfi, M., et al. (2012). Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 490, 539-542. doi: 10.1038/nature11429
199. Qu, Y., Misaghi, S., Newton, K., Maltzman, A., Izrael-Tomasevic, A., Arnott, D., et al. (2016). NLRP3 recruitment by NLRC4 during Salmonella infection. J. Exp. Med. 213, 877-885. doi: 10.1084/jem.20132234
200. Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., et al. (2011). A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70, 747-754. doi: 10.1136/ard.2010.134254
201. Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., et al. (2009). An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360, 2438-2444. doi: 10.1056/NEJMoa0809568
202. Reikine, S., Nguyen, J. B., and Modis, Y. (2014). Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front. Immunol. 5:342. doi: 10.3389/fimmu.2014.00342
203. Romberg, N., Al Moussawi, K., Nelson-Williams, C., Stiegler, A. L., Loring, E., Choi, M., et al. (2014). Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 46, 1135-1139. doi: 10.1038/ng.3066
204. Rosenwasser, L. J., Dinarello, C. A., and Rosenthal, A. S. (1979). Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J. Exp. Med. 150, 709-714. doi: 10.1084/jem.150.3.709
205. Ross, J. B., Finlayson, L. A., Klotz, P. J., Langley, R. G., Gaudet, R., Thompson, K., et al. (2008). Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J. Cutan. Med. Surg. 12, 8-16
206. Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., et al. (2012). Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2396-2406. doi: 10.1056/NEJMoa1205099
207. Russo, V., and Alikhan, A. (2016). Failure of anakinra in a case of severe hidradenitis suppurativa. J. Drugs Dermatol. 15, 772-774
208. Saraceno, R., Babino, G., Chiricozzi, A., Zangrilli, A., and Chimenti, S. (2015). PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J. Am. Acad. Dermatol. 72, e42-e44. doi: 10.1016/j.jaad.2014.10.002
209. Schnellbacher, C., Ciocca, G., Menendez, R., Aksentijevich, I., Goldbach-Mansky, R., Duarte, A. M., et al. (2013). Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr. Dermatol. 30, 758-760. doi: 10.1111/j.1525-1470.2012.01725.x
210. Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821-832. doi: 10.1016/j.cell.2010.01.040
211. Shi, H., Wang, Y., Li, X., Zhan, X., Tang, M., Fina, M., et al. (2016). NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat. Immunol. 17, 250-258. doi: 10.1038/ni.3333
212. Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., et al. (2015). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660-665. doi: 10.1038/nature15514
213. Shi, J., Zhao, Y., Wang, Y., Gao, W., Ding, J., Li, P., et al. (2014). Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187-192. doi: 10.1038/nature13683
214. Shimada, K., Crother, T. R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., et al. (2012). Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414. doi: 10.1016/j.immuni.2012.01.009
215. Shoham, N. G., Centola, M., Mansfield, E., Hull, K. M., Wood, G., Wise, C. A., et al. (2003). Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. U.S.A. 100, 13501-13506. doi: 10.1073/pnas.2135380100
216. Sibley, C. H., Chioato, A., Felix, S., Colin, L., Chakraborty, A., Plass, N., et al. (2015). A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann. Rheum. Dis. 74, 1714-1719. doi: 10.1136/annrheumdis-2013-204877
217. Siegmund, B., Fantuzzi, G., Rieder, F., Gamboni-Robertson, F., Lehr, H. A., Hartmann, G., et al. (2001). Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1264-R1273
218. Simon, A., Bodar, E. J., van der Hilst, J. C., van der Meer, J. W., Fiselier, T. J., Cuppen, M. P., et al. (2004). Beneficial response to interleukin 1 receptor antagonist in traps. Am. J. Med. 117, 208-210. doi: 10.1016/j.amjmed.2004.02.039
219. Simonini, G., Xu, Z., Caputo, R., De Libero, C., Pagnini, I., Pascual, V., et al. (2013). Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum. 65, 513-518. doi: 10.1002/art.37776
220. Sivakumar, P. V., Westrich, G. M., Kanaly, S., Garka, K., Born, T. L., Derry, J. M., et al. (2002). Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50, 812-820. doi: 10.1136/gut.50.6.812
221. Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., et al. (2013). Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239-2246. doi: 10.2337/dc12-1835
222. Sonnichsen, A., Saulite, I., Mangana, J., Kerl, K., Mehra, T., Desislava, I., et al. (2016). Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome. J. Dermatolog. Treat. 27, 436-438. doi: 10.3109/09546634.2015.1136048
223. Stack, J. H., Beaumont, K., Larsen, P. D., Straley, K. S., Henkel, G. W., Randle, J. C., et al. (2005). IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. 175, 2630-2634. doi: 10.4049/jimmunol.175.4.2630
224. Symons, J. A., Young, P. R., and Duff, G. W. (1995). Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 92, 1714-1718. doi: 10.1073/pnas.92.5.1714
225. Takei, S., Hoshino, T., Matsunaga, K., Sakazaki, Y., Sawada, M., Oda, H., et al. (2011). Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res. Ther. 13, R52. doi: 10.1186/ar3295
226. Ter Haar, N. M., Jeyaratnam, J., Lachmann, H. J., Simon, A., Brogan, P. A., Doglio, M., et al. (2016). The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the eurofever registry. Arthritis Rheumatol. 68, 2795-2805. doi: 10.1002/art.39763
227. Timper, K., Seelig, E., Tsakiris, D. A., and Donath, M. Y. (2015). Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. J. Diabetes Complications 29, 955-960. doi: 10.1016/j.jdiacomp.2015.05.019
228. Tsitsami, E., Papadopoulou, C., and Speletas, M. (2013). A case of hyperimmunoglobulinemia d syndrome successfully treated with canakinumab. Case Rep. Rheumatol. 2013:795027. doi: 10.1155/2013/795027
229. Tzanetakou, V., Kanni, T., Giatrakou, S., Katoulis, A., Papadavid, E., Netea, M. G., et al. (2016). Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 152, 52-59. doi: 10.1001/jamadermatol.2015.3903
230. Ulusoy, E., Karaca, N. E., El-Shanti, H., Kilicoglu, E., Aksu, G., and Kutukculer, N. (2015). Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report. J. Med. Case Rep. 9, 145. doi: 10.1186/s13256-015-0618-4
231. Ushio, S., Namba, M., Okura, T., Hattori, K., Nukada, Y., Akita, K., et al. (1996). Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J. Immunol. 156, 4274-4279
232. van der Burgh, R., Ter Haar, N. M., Boes, M. L., and Frenkel, J. (2013). Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin. Immunol. 147, 197-206. doi: 10.1016/j.clim.2012.09.011
233. van der Meer, J. W., Vossen, J. M., Radl, J., van Nieuwkoop, J. A., Meyer, C. J., Lobatto, S., et al. (1984). Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1, 1087-1090. doi: 10.1016/S0140-6736(84)92505-4
234. van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., and Prens, E. P. (2011). Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br. J. Dermatol. 164, 1292-1298. doi: 10.1111/j.1365-2133.2011.10254.x
235. van der Zee, H. H., and Prens, E. P. (2013). Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology 226, 97-100. doi: 10.1159/000343221
236. Vanderschueren, S., and Knockaert, D. (2013). Canakinumab in Schnitzler syndrome. Semin. Arthritis Rheum. 42, 413-416. doi: 10.1016/j.semarthrit.2012.06.003
237. Vertex. (2007). Vertex Form 10-K Annual Report. Available at: http://investors.vrtx.com/secfiling.cfm?filingID=1104659-07-15545&CIK=875320
238. Vertex. (2011). Vertex Form 10-K Annual Report. Available at: http://investors.vrtx.com/secfiling.cfm?filingID=1047469-11-1025
239. Viguier, M., Guigue, P., Pages, C., Smahi, A., and Bachelez, H. (2010). Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann. Intern. Med. 153, 66-67. doi: 10.7326/0003-4819-153-1-201007060-00030
240. Vitale, A., Rigante, D., Caso, F., Brizi, M. G., Galeazzi, M., Costa, L., et al. (2014). Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet's disease: a case series. Dermatology 228, 211-214. doi: 10.1159/000358125
241. Wannamaker, W., Davies, R., Namchuk, M., Pollard, J., Ford, P., Ku, G., et al. (2007). (S)-1-((S)-2-([1-(4-amino-3-chloro-phenyl)-methanoyl]-amino)-3, 3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R, 3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J. Pharmacol. Exp. Ther. 321, 509-516. doi: 10.1124/jpet.106.111344
242. Weber, A., Wasiliew, P., and Kracht, M. (2010). Interleukin-1 (IL-1) pathway. Sci. Signal. 3:cm1. doi: 10.1126/scisignal.3105cm1
243. Wendling, D., Prati, C., and Aubin, F. (2012). Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann. Rheum. Dis. 71, 1098-1100. doi: 10.1136/annrheumdis-2011-200743
244. Werman, A., Werman-Venkert, R., White, R., Lee, J. K., Werman, B., Krelin, Y., et al. (2004). The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc. Natl. Acad. Sci. U.S.A. 101, 2434-2439. doi: 10.1073/pnas.0308705101
245. Wilson, K. P., Black, J. A., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A., et al. (1994). Structure and mechanism of interleukin-1 beta converting enzyme. Nature 370, 270-275. doi: 10.1038/370270a0
246. Wise, C. A., Gillum, J. D., Seidman, C. E., Lindor, N. M., Veile, R., Bashiardes, S., et al. (2002). Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 11, 961-969. doi: 10.1093/hmg/11.8.961
247. Xbiotech (2017). XBiotech Meets Primary Endpoint in Phase 2 Study ofMABp1 for Treatment of Hidradenitis Suppurativa (HS). Available at: http://investors.xbiotech.com/phoenix.zhtml?c=253990&p=irol-newsArticle&ID=2246777
248. Xoma (2013). XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris. Available at: http://investors.xoma.com/releasedetail.cfm?ReleaseID=731711
249. Xoma (2015). XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study. Available at: http://investors.xoma.com/releasedetail.cfm?releaseid=923200
250. Xoma (2016). XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results. Available at: http://investors.xoma.com/releasedetail.cfm?releaseid=959741
251. Yokota, S., Imagawa, T., Nishikomori, R., Takada, H., Abrams, K., Lheritier, K., et al. (2016). Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. Clin. Exp. Rheumatol. (in press)
252. Youm, Y. H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., et al. (2015). The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263-269. doi: 10.1038/nm.3804
253. Zarchi, K., Dufour, D. N., and Jemec, G. B. (2013). Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 149, 1192-1194. doi: 10.1001/jamadermatol.2013.5377
254. Zelensky, A. N., and Gready, J. E. (2005). The C-type lectin-like domain superfamily. FEBS J. 272, 6179-6217. doi: 10.1111/j.1742-4658.2005.05031.x
255. Zhong, F. L., Mamai, O., Sborgi, L., Boussofara, L., Hopkins, R., Robinson, K., et al. (2016). Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. Cell 167, 187-202.e17. doi: 10.1016/j.cell.2016.09.001
256. Zhou, R., Yazdi, A. S., Menu, P., and Tschopp, J. (2011). A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225. doi: 10.1038/nature09663
257. Zykova, T. A., Zhu, F., Zhai, X., Ma, W. Y., Ermakova, S. P., Lee, K. W., et al. (2008). Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol. Carcinog. 47, 797-805. doi: 10.1002/mc.20437